|
KMID : 1103920140200020168
|
|
Korean Journal of Hepatology
2014 Volume.20 No. 2 p.168 ~ p.176
|
|
|
Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus
|
|
Woo Hyun-Young
Choi Jong-Young
Yoon Seung-Kew
Suh Dong-Jin
Paik Seung-Woon
Han Kwang-Hyub
Um Soon-Ho
Kim Byung-Ik
Lee Heon-Ju
Cho Mong
Lee Chun-Kyon
Kim Dong-Joon
Hwang Jae-Seok
|
|
|
Abstract
|
|
|
Background/Aims: Adefovir dipivoxil (ADV) is a nucleotide analogue that is effective against lamivudine-resistant hepatitis B virus (HBV). The aim of this study was to determine the long-term clinical outcomes after ADV rescue therapy in decompensated patients infected with lamivudine-resistant HBV.
Methods: In total, 128 patients with a decompensated state and lamivudine-resistant HBV were treated with ADV at a dosage of 10 mg/day for a median of 33 months in this multicenter cohort study.
Results: Following ADV treatment, 86 (72.3%) of 119 patients experienced a decrease in Child-Pugh score of at least 2 points, and the overall end-stage liver disease score decreased from 16±5 to 14±10 (mean ± SD, P<0.001) during the follow-up period. With ADV treatment, 67 patients (56.3%) had undetectable serum HBV DNA (detection limit, 0.5 pg/mL). Virologic breakthrough occurred in 38 patients (36.1%) and 9 patients had a suboptimal ADV response. The overall survival rate was 89.9%(107/119), and a suboptimal response to ADV treatment was associated with both no improvement in Child-Pugh score (≥2 points; P=0.001) and high mortality following ADV rescue therapy (P=0.012).
Conclusions: Three years of ADV treatment was effective and safe in decompensated patients with lamivudineresistant HBV.
|
|
|
KEYWORD
|
|
|
Adefovir dipivoxil, Lamivudine-resistant, Decompensation, Hepatitis B virus
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
   
|